<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886908</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB-BOULAKHRIF</org_study_id>
    <nct_id>NCT04886908</nct_id>
  </id_info>
  <brief_title>Comparative Retrospective Analysis of Skin Tumors of the Eyelids and Face in 2 Brussels University Hospitals Over 5 Years in Dermatology or Ophthalmology</brief_title>
  <official_title>Comparative Retrospective Analysis of Skin Tumors of the Eyelids and Face in 2 Brussels University Hospitals Over 5 Years in Dermatology or Ophthalmology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brugmann University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Skin cancers are the most common of all cancers. Their incidence has increased sharply over&#xD;
      the decades.This increase in incidence partly reflects an aging population and behavioral&#xD;
      patterns such as repeated exposure to the sun. Indeed, exposure to UV rays is the predominant&#xD;
      factor involved in the pathogenesis of these tumors, hence the fact that they mainly develop&#xD;
      in photo-exposed regions such as the cephalic extremity.&#xD;
&#xD;
      The objective of this study is to provide an epidemiological analysis of tumors in the&#xD;
      populations of both CHU Brugmann and St Pierre hospitals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Age</measure>
    <time_frame>5 minutes</time_frame>
    <description>Age of the patient at the time of diagnose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sex</measure>
    <time_frame>5 minutes</time_frame>
    <description>Sex of the patient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Name of the department in which the patient is followed</measure>
    <time_frame>5 minutes</time_frame>
    <description>Ophthalmology-CHU Brugmann hospital or Dermatology-CHU Brugmann hospital or Ophthalmology- CHU St Pierre Hospital or Dermatology-CHU St Pierre Hospital</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor anatomical location</measure>
    <time_frame>5 minutes</time_frame>
    <description>Eyelids are distributed in their different regions: internal cantus and external cantus, upper eyelid and lower eyelid. Same for the face: ears, zygomatic, forehead, temples, cheeks, nose, upper lip, lower lip, chin, nasolabial fold, preauricular area, retroauricular area, brow bone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor size</measure>
    <time_frame>5 minutes</time_frame>
    <description>Tumor size in millimeters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laterality</measure>
    <time_frame>5 minutes</time_frame>
    <description>Laterality: left, right, median</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple or single tumor</measure>
    <time_frame>5 minutes</time_frame>
    <description>Multiple or single tumor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primitive tumor or recidive</measure>
    <time_frame>5 minutes</time_frame>
    <description>Primitive tumor or recidive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk factor: phototype</measure>
    <time_frame>5 minutes</time_frame>
    <description>Phototype 1 to 6 on the Fitzpatrick scale. The Fitzpatrick scale is a numerical classification schema for human skin color. Type 1 is pale skin that always burns, never tans and type 6 is deeply pigmented dark brown to darkest brown skin that never burns.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk factor: immunosuppression (yes/no)</measure>
    <time_frame>5 minutes</time_frame>
    <description>Pathogenic or iatrogenic, history of malignant skin tumors other than melanoma, personal or family history of melanoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk factor: keratosis</measure>
    <time_frame>5 minutes</time_frame>
    <description>Actinic keratosis of the face</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk factor: solar exposition (yes/no)</measure>
    <time_frame>5 minutes</time_frame>
    <description>Lived in a sunny European country&gt; 1 year, lived in a sunny country outside Europe&gt; 1 year, sunbed use&gt; 1 session, history of solar erythema during childhood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnosis</measure>
    <time_frame>5 minutes</time_frame>
    <description>Time between the appearance of the tumor and the first consultation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Locoregional extension report (yes/no)</measure>
    <time_frame>5 minutes</time_frame>
    <description>Locoregional extension report (yes/no)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histological diagnosis of the tumor</measure>
    <time_frame>5 minutes</time_frame>
    <description>Histological diagnosis of the tumor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Healthy or invaded margins</measure>
    <time_frame>5 minutes</time_frame>
    <description>Healthy or invaded margins</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Superficial or infiltrating tumor</measure>
    <time_frame>5 minutes</time_frame>
    <description>Superficial or infiltrating tumor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic method</measure>
    <time_frame>5 minutes</time_frame>
    <description>Diagnostic method: curettage, punch, biopsy, flattening</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical management method</measure>
    <time_frame>5 minutes</time_frame>
    <description>Biopsy resection, plasty, graft, second-line healing, enucleation, additional treatment: radiotherapy, immunotherapy, liquid nitrogen</description>
  </primary_outcome>
  <enrollment type="Anticipated">373</enrollment>
  <condition>Skin Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data extraction from medical files</intervention_name>
    <description>Data extraction from medical files</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Identification of all patients who have undergone surgical excision of benign or malignant&#xD;
        facial and/or eyelid tumors over the past 5 years in the Dermatology and/or Ophthalmology&#xD;
        Departments of the CHU Saint-Pierre and CHU Brugmann hospitals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Final diagnosis confirmed by pathological analysis, epidemiological and clinical&#xD;
        information available from patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who have expressed a refusal to access their medical file or incomplete data will&#xD;
        not be taken into account.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nosria Boulakhrif</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nosria Boulakhrif</last_name>
    <phone>3224772407</phone>
    <email>nosria.boulakhrif@ulb.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Postelmans, MD</last_name>
      <phone>3224772407</phone>
      <email>laurence.postelmans@chu-brugmann.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Laurence Postelmans</investigator_full_name>
    <investigator_title>Head of Opthalmology clinic</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Eyelid Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

